A study by a team of public health researchers in London has shown that over half of new anti-cancer drugs in the EU have no beneficial effect on patients. Anti-cancer drugs produced between 2009-2013 have been shown to be ineffective on cancer patients. They have not contributed to lengthening survival rates or improving patients’ quality of life.
In the period in question, 48 anti-cancer drugs obtained authorisation for sale from the European Medicines Agency, with 68 specific indications. However, 57% of these treatments were approved without undergoing any tests to show their benefits in improving patients’ survival rates or quality of life.
These drugs have given false hope to cancer sufferers and mean extra expense for them, which in most cases is beyond their means.
What action can the Commission take to monitor these cases of ineffective anti-cancer drugs and what measures does it consider necessary to prevent such cases in future?